annual EBITDA:
-$450.13M-$89.73M(-24.90%)Summary
- As of today (June 2, 2025), MDGL annual EBITDA is -$450.13 million, with the most recent change of -$89.73 million (-24.90%) on December 31, 2024.
- During the last 3 years, MDGL annual EBITDA has fallen by -$208.68 million (-86.43%).
- MDGL annual EBITDA is now -642.30% below its all-time high of $83.00 million, reached on December 31, 2009.
Performance
MDGL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$69.56M-$14.01M(-25.22%)Summary
- As of today (June 2, 2025), MDGL quarterly EBITDA is -$69.56 million, with the most recent change of -$14.01 million (-25.22%) on March 31, 2025.
- Over the past year, MDGL quarterly EBITDA has increased by +$73.97 million (+51.54%).
- MDGL quarterly EBITDA is now -158.57% below its all-time high of $118.78 million, reached on September 30, 2009.
Performance
MDGL quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$376.15M+$73.97M(+16.43%)Summary
- As of today (June 2, 2025), MDGL TTM EBITDA is -$376.15 million, with the most recent change of +$73.97 million (+16.43%) on March 31, 2025.
- Over the past year, MDGL TTM EBITDA has increased by +$53.34 million (+12.42%).
- MDGL TTM EBITDA is now -492.78% below its all-time high of $95.77 million, reached on March 31, 2010.
Performance
MDGL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MDGL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.9% | +51.5% | +12.4% |
| 3 y3 years | -86.4% | -21.2% | -52.6% |
| 5 y5 years | -374.5% | -83.6% | -228.1% |
MDGL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.4% | at low | -25.2% | +53.0% | -52.6% | +25.2% |
| 5 y | 5-year | -374.5% | at low | -83.6% | +53.0% | -228.1% | +25.2% |
| alltime | all time | -642.3% | at low | -158.6% | +53.0% | -492.8% | +25.2% |
MDGL EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$69.56M(+25.2%) | -$376.15M(-16.4%) |
| Dec 2024 | -$450.13M(+24.9%) | -$55.55M(-46.1%) | -$450.12M(-10.4%) |
| Sep 2024 | - | -$102.99M(-30.4%) | -$502.65M(+1.6%) |
| Jun 2024 | - | -$148.05M(+3.1%) | -$494.76M(+15.2%) |
| Mar 2024 | - | -$143.53M(+32.8%) | -$429.49M(+19.2%) |
| Dec 2023 | -$360.39M(+23.9%) | -$108.08M(+13.6%) | -$360.39M(+7.1%) |
| Sep 2023 | - | -$95.10M(+14.9%) | -$336.40M(+4.8%) |
| Jun 2023 | - | -$82.77M(+11.2%) | -$320.88M(+4.2%) |
| Mar 2023 | - | -$74.44M(-11.5%) | -$307.94M(+5.9%) |
| Dec 2022 | -$290.92M(+20.5%) | -$84.09M(+5.7%) | -$290.92M(+7.2%) |
| Sep 2022 | - | -$79.57M(+13.9%) | -$271.27M(+6.5%) |
| Jun 2022 | - | -$69.84M(+21.6%) | -$254.70M(+3.4%) |
| Mar 2022 | - | -$57.41M(-10.9%) | -$246.42M(+1.9%) |
| Dec 2021 | -$241.44M(+17.1%) | -$64.44M(+2.3%) | -$241.87M(+2.1%) |
| Sep 2021 | - | -$63.00M(+2.3%) | -$236.87M(+1.9%) |
| Jun 2021 | - | -$61.56M(+16.4%) | -$232.54M(+5.1%) |
| Mar 2021 | - | -$52.87M(-11.1%) | -$221.19M(+7.3%) |
| Dec 2020 | -$206.20M(+117.4%) | -$59.44M(+1.3%) | -$206.20M(+16.7%) |
| Sep 2020 | - | -$58.67M(+16.8%) | -$176.69M(+24.3%) |
| Jun 2020 | - | -$50.21M(+32.6%) | -$142.19M(+24.0%) |
| Mar 2020 | - | -$37.88M(+26.6%) | -$114.65M(+20.9%) |
| Dec 2019 | -$94.86M(+133.7%) | -$29.93M(+23.8%) | -$94.86M(+19.5%) |
| Sep 2019 | - | -$24.17M(+6.6%) | -$79.36M(+19.3%) |
| Jun 2019 | - | -$22.68M(+25.3%) | -$66.50M(+28.8%) |
| Mar 2019 | - | -$18.09M(+25.4%) | -$51.63M(+27.2%) |
| Dec 2018 | -$40.59M(+26.9%) | -$14.43M(+27.6%) | -$40.59M(+15.9%) |
| Sep 2018 | - | -$11.31M(+45.0%) | -$35.01M(+8.3%) |
| Jun 2018 | - | -$7.80M(+10.7%) | -$32.33M(-1.9%) |
| Mar 2018 | - | -$7.05M(-20.4%) | -$32.96M(+3.0%) |
| Dec 2017 | -$31.98M(+27.1%) | -$8.85M(+2.6%) | -$31.98M(+3.6%) |
| Sep 2017 | - | -$8.63M(+2.3%) | -$30.88M(-14.9%) |
| Jun 2017 | - | -$8.43M(+38.8%) | -$36.30M(+19.0%) |
| Mar 2017 | - | -$6.08M(-21.6%) | -$30.51M(+21.2%) |
| Dec 2016 | -$25.18M(+678.7%) | -$7.75M(-44.8%) | -$25.18M(+37.2%) |
| Sep 2016 | - | -$14.05M(+432.4%) | -$18.34M(+254.5%) |
| Jun 2016 | - | -$2.64M(+257.6%) | -$5.18M(-76.3%) |
| Mar 2016 | - | -$738.00K(-19.6%) | -$21.87M(-47.0%) |
| Dec 2015 | -$3.23M(-96.1%) | -$918.40K(+4.4%) | -$41.30M(-31.3%) |
| Sep 2015 | - | -$880.00K(-95.4%) | -$60.10M(-23.4%) |
| Jun 2015 | - | -$19.34M(-4.1%) | -$78.51M(-2.7%) |
| Mar 2015 | - | -$20.16M(+2.2%) | -$80.70M(-3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | -$83.28M(-4.3%) | -$19.73M(+2.3%) | -$83.28M(-4.1%) |
| Sep 2014 | - | -$19.28M(-10.4%) | -$86.85M(-2.6%) |
| Jun 2014 | - | -$21.53M(-5.3%) | -$89.22M(-0.5%) |
| Mar 2014 | - | -$22.74M(-2.4%) | -$89.62M(+3.0%) |
| Dec 2013 | -$87.04M(+44.6%) | -$23.30M(+7.6%) | -$87.04M(+7.0%) |
| Sep 2013 | - | -$21.65M(-1.3%) | -$81.33M(+9.8%) |
| Jun 2013 | - | -$21.94M(+8.8%) | -$74.05M(+12.2%) |
| Mar 2013 | - | -$20.16M(+14.6%) | -$66.03M(+9.7%) |
| Dec 2012 | -$60.20M(+36.9%) | -$17.59M(+22.4%) | -$60.20M(+14.5%) |
| Sep 2012 | - | -$14.37M(+3.3%) | -$52.56M(+5.0%) |
| Jun 2012 | - | -$13.91M(-3.0%) | -$50.06M(+4.8%) |
| Mar 2012 | - | -$14.34M(+44.1%) | -$47.78M(+8.7%) |
| Dec 2011 | -$43.97M(+25.7%) | -$9.95M(-16.2%) | -$43.97M(+4.9%) |
| Sep 2011 | - | -$11.87M(+2.1%) | -$41.92M(+5.3%) |
| Jun 2011 | - | -$11.63M(+10.4%) | -$39.81M(+8.3%) |
| Mar 2011 | - | -$10.53M(+33.2%) | -$36.75M(+5.1%) |
| Dec 2010 | -$34.97M(-142.1%) | -$7.90M(-19.0%) | -$34.97M(+4.3%) |
| Sep 2010 | - | -$9.76M(+14.0%) | -$33.53M(-135.3%) |
| Jun 2010 | - | -$8.56M(-2.1%) | $95.01M(-0.8%) |
| Mar 2010 | - | -$8.74M(+35.2%) | $95.77M(+15.4%) |
| Dec 2009 | $83.00M(-191.2%) | -$6.46M(-105.4%) | $83.00M(+29.1%) |
| Sep 2009 | - | $118.78M(-1622.4%) | $64.28M(-180.1%) |
| Jun 2009 | - | -$7.80M(-63.7%) | -$80.21M(-15.3%) |
| Mar 2009 | - | -$21.51M(-14.6%) | -$94.73M(+4.1%) |
| Dec 2008 | -$90.99M(+44.7%) | -$25.18M(-2.1%) | -$90.99M(+12.0%) |
| Sep 2008 | - | -$25.72M(+15.2%) | -$81.27M(+15.9%) |
| Jun 2008 | - | -$22.32M(+25.6%) | -$70.12M(+8.9%) |
| Mar 2008 | - | -$17.77M(+14.9%) | -$64.42M(+2.5%) |
| Dec 2007 | -$62.87M(+13.3%) | -$15.46M(+6.2%) | -$62.86M(+5.5%) |
| Sep 2007 | - | -$14.57M(-12.3%) | -$59.58M(-0.0%) |
| Jun 2007 | - | -$16.62M(+2.5%) | -$59.59M(+38.7%) |
| Mar 2007 | - | -$16.21M(+33.1%) | -$42.97M(+60.6%) |
| Dec 2006 | -$55.50M(-19.2%) | -$12.18M(-16.5%) | -$26.75M(+83.5%) |
| Sep 2006 | - | -$14.58M(-19.3%) | -$14.58M(-19.3%) |
| Dec 2005 | -$68.72M(+56.9%) | - | - |
| Mar 2005 | - | -$18.07M(+231.4%) | -$18.07M(+231.4%) |
| Dec 2004 | -$43.80M(+60.5%) | - | - |
| Mar 2004 | - | -$5.45M | -$5.45M |
| Dec 2003 | -$27.29M(+274.2%) | - | - |
| Dec 2002 | -$7.29M(+1718.5%) | - | - |
| Dec 2001 | -$401.00K | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual EBITDA year-on-year change?
- What is Madrigal Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Madrigal Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM EBITDA year-on-year change?
What is Madrigal Pharmaceuticals annual EBITDA?
The current annual EBITDA of MDGL is -$450.13M
What is the all time high annual EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual EBITDA is $83.00M
What is Madrigal Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, MDGL annual EBITDA has changed by -$89.73M (-24.90%)
What is Madrigal Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of MDGL is -$69.56M
What is the all time high quarterly EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly EBITDA is $118.78M
What is Madrigal Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, MDGL quarterly EBITDA has changed by +$73.97M (+51.54%)
What is Madrigal Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of MDGL is -$376.15M
What is the all time high TTM EBITDA for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM EBITDA is $95.77M
What is Madrigal Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, MDGL TTM EBITDA has changed by +$53.34M (+12.42%)